Use of radioactive iodine is an essential adjuvant treatment strategy after thyroidectomy in
patients with differentiated thyroid carcinoma. Although generally safe, radioiodine therapy …

Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …

Background and Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor
(TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR1-VEGFR3), fibroblast growth …

Sorafenib has been evaluated in several Phase II and III studies in patients with locally
advanced/metastatic radioactive iodine–refractory differentiated thyroid carcinomas (DTCs) …

Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both anti
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …

目的: 探讨纳米碳负显影甲状旁腺在甲状腺癌手术中保护甲状旁腺, 避免术后甲状旁腺功能减退
的临床价值以及纳米碳对颈部淋巴结清扫的意义. 方法利用纳米碳负显影甲状旁腺 …

El radioyodo 131 es un isótopo radioactivo que se emplea exitosamente en el diagnóstico y
tratamiento de las enfermedades benignas y malignas del tiroides. Su propiedad de …

This review of radioiodine sialadenitis covers molecular mechanisms, demographics, and
analysis of quality of life. Animal and human research addressing salivary gland damage …

Background Radioactive‐iodine remnant ablation is an integral part of the papillary thyroid
carcinoma (PTC) treatment. Although a minimum dose is usually recommended, there is …

The incidence of differentiated thyroid cancer (DTC) has increased dramatically over the last
several decades. Although the etiology and clinical impact of this increase are a matter of …